Performa Ltd US LLC lessened its stake in shares of Clover Health Investments, Corp. (NASDAQ:CLOV – Free Report) by 82.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,250 shares of the company’s stock after selling 44,750 shares during the quarter. Clover Health Investments comprises about 0.0% of Performa Ltd US LLC’s investment portfolio, making the stock its 23rd biggest position. Performa Ltd US LLC’s holdings in Clover Health Investments were worth $29,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. Sigma Planning Corp acquired a new stake in Clover Health Investments during the 3rd quarter valued at $29,000. Parallax Volatility Advisers L.P. acquired a new stake in Clover Health Investments during the 3rd quarter valued at $38,000. KBC Group NV acquired a new stake in Clover Health Investments during the 3rd quarter valued at $53,000. Steph & Co. grew its holdings in Clover Health Investments by 33.3% during the 4th quarter. Steph & Co. now owns 20,000 shares of the company’s stock valued at $63,000 after buying an additional 5,000 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new stake in Clover Health Investments during the 3rd quarter valued at $97,000. Institutional investors and hedge funds own 19.77% of the company’s stock.
Clover Health Investments Stock Up 5.8 %
CLOV stock opened at $3.66 on Monday. Clover Health Investments, Corp. has a 52-week low of $0.61 and a 52-week high of $4.87. The stock’s fifty day simple moving average is $4.12 and its 200-day simple moving average is $3.63. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -18.30 and a beta of 2.00.
Insider Buying and Selling
Wall Street Analyst Weigh In
A number of equities research analysts have commented on CLOV shares. Craig Hallum started coverage on Clover Health Investments in a report on Tuesday, December 17th. They set a “buy” rating and a $6.00 target price on the stock. Canaccord Genuity Group raised their price objective on Clover Health Investments from $4.20 to $4.50 and gave the stock a “buy” rating in a report on Monday, March 3rd.
View Our Latest Stock Analysis on CLOV
About Clover Health Investments
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.
Further Reading
- Five stocks we like better than Clover Health Investments
- How to Most Effectively Use the MarketBeat Earnings Screener
- How to Build the Ultimate Everything ETF Portfolio
- High Flyers: 3 Natural Gas Stocks for March 2022
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What to Know About Investing in Penny Stocks
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding CLOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clover Health Investments, Corp. (NASDAQ:CLOV – Free Report).
Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.